Small molecules inhibiting EGFR such as erlotinib or gefitinib as well as anti-EGFR antibodies such as cetuximab were successfully tested in non-SCLC, head and neck, pancreatic and colon cancer (Ciardiello and Tortora, 2008). This evidence concerns the gene EGFR and colonic neoplasm.